New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:09 EDTAStudy shows major advantages of HER2 IQFISH pharmDx in breast cancer diagnostics
Dako, an Agilent Technologies company, announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx. The Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer. Dako introduced the cutting- edge IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours. As an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor. The French study found that Instant Quality, or IQ, FISH provides "excellent quality signals without any background staining, thus allowing excellent reading conditions." The study also points out "almost perfect agreement between IQFISH and FISH" and that IQFISH is a "safe, reliable and fast method that is easy to use in routine practice" with few reruns. The statement is significant in that the tissue came from five different laboratories using four different fixation methods. The study concludes that the highly concordant results and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. It also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
16:00 EDTAOptions Update; November 24, 2015
iPath S&P 500 VIX Short-Term Futures up 13c to 19.04, Option volume leaders: AAPL FB NFLX BAC PFE AMZN CHK TWTR GE SUNE DE AGN AAL MSFT INTC X BABA A
15:38 EDTAOptions with increasing volume: SUNE HPQ TSM PMCS TSO EPI A DE CREE
November 19, 2015
16:10 EDTAAgilent increases cash dividend to 11.5c per share
Subscribe for More Information
November 17, 2015
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
November 16, 2015
18:26 EDTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:10 EDTAAgilent reports Q4 LSAG revenue down 4% to $515M
Subscribe for More Information
16:09 EDTAAgilent sees FY16 adjusted EPS $1.85-$1.91, consensus $1.97
Sees FY16 revenue $4.15B-$4.17B, consensus $4.21B.
16:08 EDTAAgilent sees Q1 adjusted EPS 42c-44c, consensus 47c
Subscribe for More Information
16:07 EDTAAgilent reports Q4 adjusted EPS 50c, consensus 47c
Subscribe for More Information
15:02 EDTANotable companies reporting after market close
Subscribe for More Information
November 11, 2015
08:44 EDTAAgilent November volatility elevated into Q3 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use